Heart Health Claim for Soy Protein in ANZ Set to Accelerate Innovation – IFF

Why It Matters

The claim lets manufacturers label products with a proven cardiovascular benefit, driving growth for plant‑based protein and helping address the region’s high cholesterol risk.

Key Takeaways

• FSANZ approves heart‑health claim for isolated soy protein (ISP).
• Products with 20‑25 g ISP can display the claim in ANZ.
• Over 80 clinical trials show ISP lowers LDL cholesterol.
• Claim already recognized in 11 countries, now added to ANZ.
• IFF expects growth in functional drinks, bars, and plant‑based milks.

Pulse Analysis

The Food Standards Australia New Zealand (FSANZ) has just granted a general‑level heart‑health claim for isolated soy protein (ISP), marking the first time the ANZ Food Standards Code will allow manufacturers to label products that deliver 20‑25 g of ISP per day as supportive of cardiovascular health. The decision follows a rigorous review of more than 80 randomized controlled trials that demonstrate a modest but consistent reduction in LDL cholesterol. With roughly 60 % of Australian adults classified as dyslipidemic, the claim addresses a sizable public‑health gap and aligns with the region’s tightening nutrition‑labeling rules.

For ingredient supplier IFF, the approval unlocks a new wave of formulation possibilities across ready‑to‑drink beverages, protein bars, fortified plant milks and hybrid dairy‑plant products. Brands can now pair the functional benefits of ISP—complete amino‑acid profile and texture‑enhancing properties—with a scientifically backed health message, a combination that resonates with consumers seeking evidence‑based, sustainable nutrition. The claim also differentiates products in a crowded plant‑based market, where taste and proven health outcomes are becoming decisive purchase drivers. Early adopters are likely to leverage the claim to command premium shelf space and pricing.

Globally, ISP already carries heart‑health endorsements in the United States, Canada, Japan and nine other jurisdictions, and the ANZ approval brings the region in step with those markets. Analysts expect the regulatory win to accelerate investment in soy‑based innovation, prompting collaborations between IFF, food manufacturers and research institutions to refine dosage delivery and sensory performance. While supply chain constraints for non‑GMO soy could pose a hurdle, the long‑term outlook is positive: a clearer label claim should spur consumer trial, expand market share for plant proteins, and contribute to broader cholesterol‑management strategies.